SlideShare a Scribd company logo
CHAIR PERSON : PROF.DR.RAVI .K
CO CHAIR PERSON:ASSOC.PROF.DR.KAVYA
PRESENTER:DR.ASHOKVARDHANREDDY.T
 PATHOPHYSIOLOGY OF ASCITES
 REFRACTORY ASCITES
 DEFINITION,
 CAUSES
 PATHOPHYSIOLOGY
 TREATMENT
 Ascites is the most common complication
in patients with cirrhosis.
 It develops as a consequence of a severe
impairment of liver function and portal
hypertension.
PORTAL HYPERTENSION
Nitric oxide
SPLANCHNIC VASO
DILATATION
RENAL SODIUM
RETENTION
OVERFILL OF
INTRA VASCULAR
VOLUME
ASCITES
Sympathetic
Activity,
RAAS
 The central event of ascites formation in
cirrhosis is a splanchnic arterial vasodilatation
secondary to portal hypertension.
 1 Backward theory :pressure due to resistance in
liver
 2 Forward theory :splanchnic bed vaso
dilatation.
 3 Overflow theory-Increased plasma volume
increases hepatic lymph formation.
 4 Underfilling theory – Arterial under filling
 Clinical examination
 Usg abdomen- liver size
 portal vein
 homogenous – transudate
multiple echogenic shadows –
exudate
Fluid collects first in flanks,right upper
quadrant ,para colic gutter , and around liver
 Multiple echos ,septations ,fibrous strands
indicates ascites unrelated to portal
hypertension.
 Grade 1-Detectable by ULTRASOUND
abdomen.
 Grade 2-symmetrical distension of
abdomen.shifting dullness present.
 Grade 3 :Marked abdominal distension.
fluid thrill present
 Total ascitic fluid protein is inversely
related to portal hypertension.
 As the disease severity increases ,protein
levels decrease
 SBP develops in total ascitic fluid protein <1
g/dl
 High concentration of macrophages is found
in ascitic fluid
 Bloody ascites occurs in 2 % patients
 In patients with cirrhosis a complex coagulation
process within the ascitic fluid results in intra
peritoneal coagulation and primary and
secondary fibrinolysis.
 The macrophages of ascitic fluid synthesize
vasodilatatory substances (e.g., nitric oxide,
adreno medullin, vascular endothelial growth
factor). The pathophysiologic significance of this
finding is unknown.
 The concentration of leptin and vascular
endothelial growth factor is higher in ascitic
fluid than in plasma .
Ascitic fluid has anti bacterial activity, which
correlates directly with the total ascitic fluid
protein concentration . Substances such as
complement, fibronectin, cytokines, and are
implicated in this effect.
Infusion of ascitic fluid within the general
circulation is associated with important biologic
effects, the most important being intravascular
coagulation and fever.
 A single layer of mesothelial cells covers
the peritoneal surface of the diaphragm over
a connective tissue matrix with a very rich
plexus of terminal lymphatic vessels
(lymphatic lacunae) .
 Lacunae are large enough to allow the
passage of erythrocytes, connect the
peritoneal cavity with the lumen of the
terminal lymphatics.
 The submesothelial lymphatic plexus drains into
parasternal trunks on the ventral thoracic wall,
right lymphatic duct, and right subclavian or
internal jugular vein.
During inspiration, lacunae are emptied
During expiration, the gaps open and
communication is re established.
 The estimated mean rate of ascitic fluid
reabsorption is 1.4 L/day, ranging from less than
0.5L to more than 4L.
 Furosemide and spironolactone are the most
commonly used drugs
o Furosemide and spironolactone are most
commonly used drugs
 Two different approaches for patients with
cirrhosis and ascites-
 1 step care approach –sodium restriction
 spironolactone 100 mg/day
 No response in 4 days

 200 mg/day
 no response in 4 days
 400 mg/day
 No response at 400 mg spironolactone /day
start furosemide 40 mg /day
Can be increased to 160 mg /day
Dose escalated by 40 mg every 2 days.
 Simultaneous administration of Na
restriction ,
 Spironolactone 100 mg/day
 Furosemide 40 mg/day
 4 days
dose increased to 200 spironolactone
+
80 mg furosemide
 Complications of diuretics
 Renal failure
 Hyponatremia
 Hepatic encephalopathy
 Hypo/hyper kalemia
 Hyper uricemia
 Furosemide challenge test-
 80 mg furosemide iv
 urine collection for next 8 hrs
 Urine sodium <50 m Eq for 8 hrs is indicative
of resistance
 Random urine Na/k ratio >1
 Indicates 24 hr urine Na excretion >78 m Mol
/day.
 WORLD JOURNAL OF GASTRO ENTEROLOGY
 SENOUSY ETAL , 2009 JANUARY
 Once in 2 weeks
 Check body weight
 BP
 Look for orthostatic symptoms
 serum electrolytes
 Blood urea ,serum creatinine
 WORLD JOURNAL OF GASTRO ENTEROLOGY
 JANUARY 2009
 Refractory ascites applies to the ascites that
cannot be mobilized(minimal /no weight
loss)despite adherence to sodium
restriction(88 m eq/2000 mg/day) or the
early recurrence of which (i.e., after
therapeutic paracentesis) cannot be
prevented by medical therapy.
 International ascites club
 Arroyo V etal .Hepatology ,1996 .
 1 DIURETIC RESISTANT ASCITES:
 Loss of body weight <200 g /day after 4 days
of treatment or recurrence cannot be
prevented even after
dietary sodium restriction <50 m eq/day {<90
m Eq/day EASL}
 Furosemide 160 mg/day AND
 Spironolactone 400 mg/day { SCHIFFS DISEASES OF LIVER}/
600 mg /day {HARRISONS TEXT BOOK OF INTERNAL MEDICINE} for at
least 1 week.
 Recurs rapidly after therapeutic paracentesis
with in 4 weeks {AASLD}
 2 DIURETIC INTRACTABLE ASCITES:
 Ascites cannot be mobilised / recurrence
cannot be prevented due to diuretic induced
complications that precludes use of effective
diuretic dose.
 Eg –Hepatic encephalopathy in absence of
any precipitating cause
 Increase in creatinine levels >100% to a value
>2 mg %
 Decrease in serum sodium level by >10
mEq/L to a concentration <125 mEq/L.
 Decrease of serum potassiumlevel to <3
mEq/L or an increase to >6 mEq/L despite
appropriate measures to normalize potassium
concentration.
 Most patients with cirrhosis and ascites with
serum creatinine >1.2 mg/dl reflects
decrease in renal blood flow and GFR by >50
% .
 Renal hypo perfusion

 Impairment of access of diuretics to
effective sites on the tubular cells
 excessive reabsorption of Na + in PCT
 Reduced delivery of sodium to ascending
limb of loop of henle and the distal nephron
 Peritoneo venous shunt.
 TIPS(Trans jugular Intrahepatic Portosystemic
Shunt).
 Therapeutic paracentesis .
 Remove ascitic fluid before inserting
prosthesis
 To avoid massive passage of ascitic fluid in to
circulation
 Pulmonary edema ,
 Variceal bleed,
 Intravascular coagulation.
 Prophylactic administration of anti
staphylococcal antibiotics is recommended
atleast for 3 days.
.
Passage of ascitic fluid from abdominal cavity to
systemic circulation
Sustained expansion of circulating blood volume
Renin,nor epinephrine,ADH, response to
diuretics
Its very good that patient feels better
immediately,and it appears rational therapy for
refractory ascites …….BUT
 40 % obstruction of shunt with
in 1 yr
 {Fibrin deposits in valve / catheter,thrombus
in venous limb of prosthesis, thrombus in SVC
causing obstruction}
 10 % small bowel obstruction in
long term {intra peritoneal fibrosis}
 Remove the prosthesis and insert new one
 1 st described by CELSUS in 20 B.C
 Ludvig van beethoven in 1827 received large
volume paracentesis ….2 days after which he
expired.
 NECESSITY –
 10-20 % of patients are diuretic resistant.
 Complications are high with diuretics.
 Diuretics take time to reduce ascites.
 Therapeutic paracentesis is considered the
best therapy for tense ascites in cirrhosis .
 It considerably shortens hospital stay ,the cost
of treatment, incidence of
complications during hospitalization than
among those treated with diuretics .
 1-
 Repeated large volume paracentesis.
 Ascites can leak in to abdominal
wall/outside.
 2-
 Total paracentesis
 Fluid is removed at once
 Less complication rate
 7 cm length
 17 G
 Blunt edged cannula with side holes
 Left lower quadrant
 To be connected to suction pump,30 – 60
mins( free flow of ascitic fluid is
recommended now)
 Precaution – patient should recline on
opposite side for 2 hrs to prevent leakage of
ascitic fluid
 Few studies –no apparent major changes in
circulatory function
 Arterial pressure
 PR – No change
 Ascites disappears
 Creatinine and electrolytes –no change
 Intra thoracic pressure
Circulatory function
 Stroke volume,cardiac output
 cardio pulmonary pressure , Renin
 plasma renin levels which peaks on 6
 th day of paracentesis leads to
angiotensin II,nor epinephrine
 vaso constriction of intrahepatic
vessels-thereby resistance portal
pressure

 Patients admitted for tense ascites and not
on treatment and in 1 week hospital stay-16
%
 Paracentesis induced circulatory
dysfunction in patients not on plasma
volume expansion -75 %
 Patients on polygeline {8g/l ascitic fluid}-33-
38 %
 Patients on albumin {8g/l ascitic fluid}-11-
18%
 If amount drained is <5 l – incidence is 16%
with albumin vs 18 % with synthetic plasma
expander .
 If 5-9 l- incidence 19% vs 30 %
 >9 l 52 % with synthetic plasma expanders.
 Risk of peritoneal bleeding 0.5-1 %
 Leakage of ascitic fluid from tap
site…managed by z technique.
 PICD (Paracentesis induced circulatory
dysfunction.)
 Plasma renin increase > 50 % of pre
treatment value to above 4 ng/ml on 6 th
day after paracentesis.
 Spontaneous bacterial peritonitis
 Creatinine >3 mg/dl
 Severe hepatic encephalopathy
 Hypotension
 Disseminated intra vascular coagulation
 Caution in patients with abdominal adhesions
 Albumin infusion
 Incidence of Hyponatremia 3.8 %
 renal impairment -0%
 No plasma expander-
 Hyponatremia – 17 %
 Renal impairment 11 %
 If we drain < 5 l ascitic fluid –
 less expensive synthetic plasma expanders -8g/l
ascitic fluid can be used
If > 5 l is drained albumin infusion is advised 8 g /l
50% immediately after paracentesis
6 hrs
50 % to be given
Diuretics to be continued If BUN and serum
creatinine are normal –
200 mg / day spiranolactone or 40 mg /day
furosemide + 100 mg /day spironolactone …..
paracentesis Leveen shunt
Ascites episodes 125 38
Lvs obstruction 40 % in 1 yr
Days in hospital 48 +/-6 44+/- 6
Survival 1 yr 57 % 44%
 Innovative idea of usage of cvp catheter for
drainage of ascitic fluid was tried to reduce
the hospitalisation rate ,and so morbidity
 Shahram agah,sahar tavakoli,Hajar nikbakth,Mehrdokht
Najafi,Abdolreza al agha
 Colorectal research center ,IRAN UNIVERSITY OF MEDICAL
SCIENCES
 Precise percussion and point of highest fluid
accumulation should be marked for puncture
site.
 Local anesthesia with 5-10 ml of 2 %
lignocaine inj.
 Punctured using 18 G needle
 Perpendicular to skin
 Guide wire passed through needle.
 Remove the needle .
 Pass the catheter through guide wire till wing
meet the skin .
 catheter outlet attached to urine bag .
 Drainage started at the rate of 250 -500
ml/hr.
 Vital signs checked every 15 mins once
during procedure.
 8 g Albumin is infused for 1 l of ascitic fluid
drained.
 After complete drainage of ascitic fluid
 {< 100 ml fluid drained /day}.

All patients were prescribed diuretics ,low
sodium diet on followed up.
 Re admission rate was 1.9 in 1 yr follow up
 (2-4 times in routene paracentesis)
 Serum sodium showed no significant change ,
 Potassium – no significant change
 Creatinine decreased with in 24 hrs.
 Trans jugular intra hepaic portosystemicshunt

 Endogenous vaso constrictor
system
 Renal function , GFR,response to
diuretics
 Lymph formation in liver and other
splanchnic organs
 marked in renin, aldosterone with in 1
week
 ADH and Nor epinephrine in 2
weeks
 GFR increases ,
 urinary excretion of Na increases in 1-2
weeks
 Free water clearance
 TIPS porto caval gradient
 In 358 patients with refractory ascites with
TIPS
 Porto caval gradient decreased from 20.9
10 mm Hg
 Portal venous pressure 29.4 mm Hg
21.8 mm Hg
 Ascites resolves in 1-3 months
 10 % patients doesn’t respond to TIPS
 Diuretics are required in >95 % cases
 TOTAL BILIRUBIN >5 mg/dl
 PT INR>2
 CHILD PUGH SCORE>11
 MELD SCORE >18
 HEPATIC ENCEPHALOPATHY >/= 2
 INFECTIONS
 RENAL FAILURE
 CARDIOPULMONARY DECOMPENSATION
 Most common – hepatic encephalopathy
 Occurs in > 40 % patients
 Responds to standard therapy
 May require to decrease the stent size
 Early mortality {with in 30 days} occurs in 12
%
 Late mortality in 40 %
 Worsening of Liver function tests due to
liver ischemia due to diversion of portal
blood to systemic circulation
 Cardiac failure
 Migration of stent to right heart or lung
 Endo tipssitis
 Transient intra vascular hemolysis
 Reference –API Medicine update ..Aabha nagral
study Type of
ascites
Control of
ascites
Hepatic
encephalop
athy
survival
LEBREC etal
1994
Refractory
ascites
Better with
TIPS
NO
difference
Worse with
TIPS
ROSSLE etal Refractory
& recidivant
Better with
TIPS
No
difference
Better with
TIPS
GINES etal Refractory Better with
TIPS
Worse with
TIPS
No
difference
SANYAL etal Refractory Better with
TIPS
Worse with
TIPS
No
difference
SALERNO
etal2004
Refractory
& recidivant
Better with
TIPS
Worse with
TIPS
Better with
TIPS
 TIPS changes course of cirrhosis from ascites
to hepatic encephalopathy without improving
overall results of paracentesis , in relation to
length of hospitalisation .
 Medical therapy –
 Beta blockers contra indicated ( hypotension)
 Midodrine 7.5 mg tid can be started
 urine output
 urine sodium
 mean arterial pressure
 Diuretic resistant diuretic sensitive
 Refractoriy ascites
 discontinue betablockers,
 add midodrine 7.5 mg
 tid
 If not responding
 Consider 1 serial therapeutic paracentesis
 2 liver transplant
 3 TIPS
 4 experimental medical treatment
 Large volume therapeutic paracentesis-{
atleast 5 L}
 Total paracentesis is recommended
 Once in 2 weeks or once in 1 week
 Colloid replacement- In a randomised
control study 105 patients with tense
ascites-
 Albumin 1g/L vs without albumin infusion
was studied
 Significant increase in renin ,
 creatinine,
 serum electrolytes are observed without
albumin infusion.
 But no more clinical morbidity and mortality
o hr Terlpressin iv 1 mg starting of
paracentesis
8 hr iv 1 mg repeat +tab midodrine
5 mg tid
16 hr iv 1 mg repeat
EQUIVALENT to albumin in suppressing
renin
 Chronic therapeutic paracentesis is reserved
for only 10 % patients who fail diuretics
 As it causes hypo proteinemia,
 Malnutrition
 Increased infections
 Prognosis of refractory ascites –
 Bad.21 % die in 6 months
 TIPS vs Large volume therapeutic paracentesis
 Significant survival advantage
 Better control of ascites
 More chances of encephalopathy
 Caution- patients with renal parenchymal
disease on dialysis may not respond well to TIPS
 Do not with held diuretics after TIPS
 New entry- poly tetra fluoro ethylene coated
Stent is better ,patency duration is
increased,greater survival;
 Why?
 Poor long term patency
 Increased infections
 No increased survival compared to medical
therapy
 Only in patients who are not candidates for
TIPS/liver transplant/not fit for serial
therapeutic paracentesis
 1 retrospective study on efficacy of weekly
albumin infusion of 50 g in reducing weight in
patients with refractory ascites who are not
candidates for TIPS ….result awaited
 Pilot Randomised control study -0.075 mg
oral clonidine bid vs placebo in patients with
cirrhosis ,with ascites and plasma nor
Epinephrine> 300 pg/ml--- more rapid
mobilisation of ascites with fewer
complications
 3 pilot Randomised control studies
 Paracentesis + albumin
 Vs
 Clondine + spironolactone
 In patients with refractory ascites and
plasma nor epinephrine >300 pg/ml
 Result – fewer hospitalisation in latter group
.
Device that drains ascitic fluid into urinary
bladder.
ALFA pump system (Automated low flow ascites
pump).
Flow : catheter in abdominal cavity
subcutaneously inserted battery powered
pump catheter connected to bladder.
Pump is recharged wirelessly through skin
Removes 5 L per charge.
 Severe irritation in bladder
Recurrent urinary tract infections.
Pyelo nephritis
Not approved for practise.
 Median survival period for refractory ascites
is 6 months
 1 st best option is liver transplant
 MELD score >18
 Hyponatremia <130 mEq/l
 LOW Mean arterial pressure
 Low urine sodium <50 m eq/l
 High child pughscore >11
 All determine duration of survival
 LVP is the 1 st line treatment
 Diuretics must be discontinued if dys
electrolytemia/renal failure/hepatic
encephalopathy occurs.Continue diuretics
only when urine sodium >30 mMol/l
 V2 receptor antagonists – satavaptan + fixed
dose diuretics is under phase II trials
 Improves Na levels,increases weight
loss,decreases recurrence of ascites.
 TIPS is recommended only if very frequent
requirement of LVP/ineffective paracentesis
(loculated)
 Role of aquaretics
 phase III clinical trials –satavaptan +
diuretics showed no further improvement in
control of ascites
 Increased morbidity and mortality was also
observed
 Recently Tolvaptan is approved for
management of refractory ascites..
 Forty cirrhotic patients with refractory or
recurrent ascites were prospectively studied
after long term administration of midodrine
plus standard medical therapy (n = 20) or
standard medical therapy alone (n = 20) in a
randomized controlled trial at a tertiary
centre. Virendra singh etal …PGIMER
 A significant increase in urinary volume,
urinary sodium excretion, mean arterial
pressure, and decrease in plasma renin
activity (p <0.05) was noted after 1 month of
midodrine administration.
 There was also a significant decrease in
cardiac output and an increase in systemic
vascular resistance after midodrine therapy
at 3 months (p <0.05)
There was no change in glomerular filtration
rate and model for end-stage liver disease
(MELD) score.
Midodrine addition is superior to standard
medical therapy alone in the control of ascites
(p = 0.013) at 3 months. The mortality rate in
the standard medical therapy group was
significantly higher than the midodrine group
(p <0.046). There was no significant difference
in the frequency of various complications at
the end of follow-up.
 ANNALS OF HEPATOLOGY ..Amarapurkar etal
 Back ground- use of covered TIPS was shown
to improve the shunt patency rate over
uncovered TIPS.Retrospective analysis was
performed to assess efficacy of both
 Methods-over 10 yr period,selected patients
who require LVP atleast 2 times in a
month,or intolrant to LVP,or unwilling to
undergo further LVP were treated with TIPS
 12 PATIENTS 11 PATIENTS
 Uncovered TIPS PTFE covered
TIPS
 Age 56.1+/_4.5 yrs 55.8+/_5.2
yrs
 Male : female-5:1 male
:female-8:3
 Followed up with –clinical examination,USG
abdomen,doppler examination ,every
monthly for 3 months,and every 3 monthly
thereafter.
 Clinical success= disappearance of ascites in
1 month
 Technical success =post TIPS reduction of
PPG (porto systemic pressure gradient) <12
mm Hg.
 Appearance of encephalopathy
 TIPS dysfunction= >50 %reduction in flow
velocity ,> 50 % shunt stenosis,or increase in
PPG> 12mm Hg
GROUP A GROUP B
CLINICAL SUCCESS 63.3% 81.8%
TECHNICAL SUCCESS 63.3% 81.8%
HEPATIC
NCEPHALOPATHY
60% 54.4%
MORTALITY AT 1 YR 70% 63.3%
TIPS DYSFUNCTION
REQUIRING RE
INTERVENTION 50% 0%
 Harrisons text book of internal medicine 18th
edition
 Schiffs diseases of liver 11th edition.
 Sherlock’s diseases of liver and biliary tract
12th edition
 AASLD guide lines 2013
 EASL guidelines of liver disease 2012
 Indian journal of gastro enterology. .volume
33,isssue4 ,august 2014.
 Clinical gastroenterology by Rajiv mehta 3rd
edition.
Thanks to
• Dr.RAVI .K professor of medicine
• Dr.SUSHRUTH Surgical gastro
enterologist. PMSSY

More Related Content

What's hot

Cardiorenal Syndrome
Cardiorenal SyndromeCardiorenal Syndrome
Cardiorenal Syndrome
Sujay Iyer
 
Ckd mbd
Ckd mbdCkd mbd
Ckd mbd
Harsh shaH
 
Membranous nephropathy
Membranous nephropathyMembranous nephropathy
Membranous nephropathyVishal Golay
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckd
Praveen Nagula
 
Renovascular hypertension(rvh)
Renovascular hypertension(rvh)Renovascular hypertension(rvh)
Renovascular hypertension(rvh)
Rishit Harbada
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
Chetan Ganteppanavar
 
RENAL TUBULAR ACIDOSIS
RENAL TUBULAR ACIDOSISRENAL TUBULAR ACIDOSIS
RENAL TUBULAR ACIDOSIS
Parth Nathwani
 
Spontaneous Bacterial Peritonitis (SBP)
Spontaneous Bacterial Peritonitis (SBP)Spontaneous Bacterial Peritonitis (SBP)
Spontaneous Bacterial Peritonitis (SBP)
Basant Raj Joshi
 
Budd chiari syndrome
Budd chiari syndromeBudd chiari syndrome
Budd chiari syndrome
Jino Justin
 
Acute on Chronic Liver Failure (ACLF)
Acute on Chronic Liver Failure (ACLF)Acute on Chronic Liver Failure (ACLF)
Acute on Chronic Liver Failure (ACLF)
Pratap Tiwari
 
hypokalemic periodic paralysis
hypokalemic periodic paralysishypokalemic periodic paralysis
hypokalemic periodic paralysislaxmikant joshi
 
Rhabdomyolysis .-dr.-osama-2017
Rhabdomyolysis .-dr.-osama-2017Rhabdomyolysis .-dr.-osama-2017
Rhabdomyolysis .-dr.-osama-2017
FarragBahbah
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
subramaniam sethupathy
 
Chronic liver disease
Chronic liver diseaseChronic liver disease
Chronic liver disease
Dr. Abhinav Agarwal
 
Approach to nephrotic syndrome
Approach to nephrotic syndromeApproach to nephrotic syndrome
Approach to nephrotic syndrome
Abhay Mange
 
Acute liver failure
Acute liver failureAcute liver failure
Acute liver failure
Saqib Pervez
 
APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA
Dr Narendra singh
 
Polyuria
PolyuriaPolyuria
Polyuria
Abino David
 
Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis
Praveen RK
 

What's hot (20)

Cardiorenal Syndrome
Cardiorenal SyndromeCardiorenal Syndrome
Cardiorenal Syndrome
 
Ckd mbd
Ckd mbdCkd mbd
Ckd mbd
 
Membranous nephropathy
Membranous nephropathyMembranous nephropathy
Membranous nephropathy
 
Management of dm in ckd
Management of dm in ckdManagement of dm in ckd
Management of dm in ckd
 
Renovascular hypertension(rvh)
Renovascular hypertension(rvh)Renovascular hypertension(rvh)
Renovascular hypertension(rvh)
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
 
RENAL TUBULAR ACIDOSIS
RENAL TUBULAR ACIDOSISRENAL TUBULAR ACIDOSIS
RENAL TUBULAR ACIDOSIS
 
Spontaneous Bacterial Peritonitis (SBP)
Spontaneous Bacterial Peritonitis (SBP)Spontaneous Bacterial Peritonitis (SBP)
Spontaneous Bacterial Peritonitis (SBP)
 
Budd chiari syndrome
Budd chiari syndromeBudd chiari syndrome
Budd chiari syndrome
 
Acute on Chronic Liver Failure (ACLF)
Acute on Chronic Liver Failure (ACLF)Acute on Chronic Liver Failure (ACLF)
Acute on Chronic Liver Failure (ACLF)
 
hypokalemic periodic paralysis
hypokalemic periodic paralysishypokalemic periodic paralysis
hypokalemic periodic paralysis
 
Rhabdomyolysis .-dr.-osama-2017
Rhabdomyolysis .-dr.-osama-2017Rhabdomyolysis .-dr.-osama-2017
Rhabdomyolysis .-dr.-osama-2017
 
Renal tubular acidosis
Renal tubular acidosisRenal tubular acidosis
Renal tubular acidosis
 
Chronic liver disease
Chronic liver diseaseChronic liver disease
Chronic liver disease
 
Approach to nephrotic syndrome
Approach to nephrotic syndromeApproach to nephrotic syndrome
Approach to nephrotic syndrome
 
Acute liver failure
Acute liver failureAcute liver failure
Acute liver failure
 
Hepatorenal syndrome
Hepatorenal syndromeHepatorenal syndrome
Hepatorenal syndrome
 
APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA APPROACH TO PANCYTOPENIA
APPROACH TO PANCYTOPENIA
 
Polyuria
PolyuriaPolyuria
Polyuria
 
Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis Post streptococcal glomerulonephritis
Post streptococcal glomerulonephritis
 

Viewers also liked

Treatment of refractory ascites
Treatment of refractory ascitesTreatment of refractory ascites
Treatment of refractory ascites
Siti Nurul Afiqah Johari
 
Refractory ascites Dr Ashok v reddy.pptx 20 nov
Refractory ascites  Dr Ashok v reddy.pptx 20 novRefractory ascites  Dr Ashok v reddy.pptx 20 nov
Refractory ascites Dr Ashok v reddy.pptx 20 novashokvardhan reddy
 
Approach to ascites
Approach to ascitesApproach to ascites
Approach to ascites
Bikash Praharaj
 
Ascitic tap or paracentesis
Ascitic tap or paracentesisAscitic tap or paracentesis
Ascitic tap or paracentesis
Ma Icban
 
Guidelines in ascites
Guidelines in ascitesGuidelines in ascites
Guidelines in ascitesMarlon Turaja
 
MYASTHNIA GRAVIS
MYASTHNIA  GRAVISMYASTHNIA  GRAVIS
MYASTHNIA GRAVIS
pranay konda
 

Viewers also liked (9)

Treatment of refractory ascites
Treatment of refractory ascitesTreatment of refractory ascites
Treatment of refractory ascites
 
Refractory ascites Dr Ashok v reddy.pptx 20 nov
Refractory ascites  Dr Ashok v reddy.pptx 20 novRefractory ascites  Dr Ashok v reddy.pptx 20 nov
Refractory ascites Dr Ashok v reddy.pptx 20 nov
 
Approach to ascites
Approach to ascitesApproach to ascites
Approach to ascites
 
Ascitic tap or paracentesis
Ascitic tap or paracentesisAscitic tap or paracentesis
Ascitic tap or paracentesis
 
Guidelines in ascites
Guidelines in ascitesGuidelines in ascites
Guidelines in ascites
 
Approach To a Patient with Ascitis
Approach To a Patient with AscitisApproach To a Patient with Ascitis
Approach To a Patient with Ascitis
 
MYASTHNIA GRAVIS
MYASTHNIA  GRAVISMYASTHNIA  GRAVIS
MYASTHNIA GRAVIS
 
Ascitis
AscitisAscitis
Ascitis
 
Ascites
AscitesAscites
Ascites
 

Similar to Refractory ascites

Portal Hypertension Final.pptx hepatobiliary surgery
Portal Hypertension Final.pptx hepatobiliary surgeryPortal Hypertension Final.pptx hepatobiliary surgery
Portal Hypertension Final.pptx hepatobiliary surgery
prakashPatel156238
 
M Hussnain Raza, Portal Hypertension.pptx
M Hussnain Raza, Portal Hypertension.pptxM Hussnain Raza, Portal Hypertension.pptx
M Hussnain Raza, Portal Hypertension.pptx
draadii305
 
Portal+Hypertension.pptx
Portal+Hypertension.pptxPortal+Hypertension.pptx
Portal+Hypertension.pptx
kamal199155
 
Portal+Hypertension.ppt hepatobiliary system
Portal+Hypertension.ppt hepatobiliary systemPortal+Hypertension.ppt hepatobiliary system
Portal+Hypertension.ppt hepatobiliary system
prakashPatel156238
 
PORTAL HTN spleno renal shunt.ppt
PORTAL HTN spleno renal shunt.pptPORTAL HTN spleno renal shunt.ppt
PORTAL HTN spleno renal shunt.ppt
anaesthesiaESICMCH
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
Gunjan Malviya
 
new panc.pptx
new panc.pptxnew panc.pptx
new panc.pptx
DevaLekshmi1
 
Ascites ( Diagnosis and management ).pdf
Ascites ( Diagnosis and management ).pdfAscites ( Diagnosis and management ).pdf
Ascites ( Diagnosis and management ).pdf
Mohamed Wifi
 
Liver disease
Liver diseaseLiver disease
Liver disease
Eman Rasmy
 
Upper gi bleeding
Upper gi bleedingUpper gi bleeding
Upper gi bleeding
SharmeenAslam2
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
Bharath Anantha
 
Diaysis john
Diaysis johnDiaysis john
Diaysis john
Johny Wilbert
 
Management of Shock
Management of Shock Management of Shock
Cardiology with pharmacology for nurses
Cardiology with pharmacology for nursesCardiology with pharmacology for nurses
Cardiology with pharmacology for nurses
tentance
 
Pancreatic transplant.dr quiyum
Pancreatic transplant.dr quiyumPancreatic transplant.dr quiyum
Pancreatic transplant.dr quiyum
MD Quiyumm
 
Shock nekaba
Shock nekabaShock nekaba
Shock nekaba
Ahmed-shedeed
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
Mohit Chaudhary
 
Acute Renal Failure1
Acute Renal Failure1Acute Renal Failure1
Acute Renal Failure1TKeresztes
 
Chyluria and its Mangagement
Chyluria and its MangagementChyluria and its Mangagement
Chyluria and its Mangagement
Rohan Sharma
 

Similar to Refractory ascites (20)

Portal Hypertension Final.pptx hepatobiliary surgery
Portal Hypertension Final.pptx hepatobiliary surgeryPortal Hypertension Final.pptx hepatobiliary surgery
Portal Hypertension Final.pptx hepatobiliary surgery
 
M Hussnain Raza, Portal Hypertension.pptx
M Hussnain Raza, Portal Hypertension.pptxM Hussnain Raza, Portal Hypertension.pptx
M Hussnain Raza, Portal Hypertension.pptx
 
Portal+Hypertension.pptx
Portal+Hypertension.pptxPortal+Hypertension.pptx
Portal+Hypertension.pptx
 
Portal+Hypertension.ppt hepatobiliary system
Portal+Hypertension.ppt hepatobiliary systemPortal+Hypertension.ppt hepatobiliary system
Portal+Hypertension.ppt hepatobiliary system
 
PORTAL HTN spleno renal shunt.ppt
PORTAL HTN spleno renal shunt.pptPORTAL HTN spleno renal shunt.ppt
PORTAL HTN spleno renal shunt.ppt
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
 
new panc.pptx
new panc.pptxnew panc.pptx
new panc.pptx
 
Ascites ( Diagnosis and management ).pdf
Ascites ( Diagnosis and management ).pdfAscites ( Diagnosis and management ).pdf
Ascites ( Diagnosis and management ).pdf
 
Liver disease
Liver diseaseLiver disease
Liver disease
 
Upper gi bleeding
Upper gi bleedingUpper gi bleeding
Upper gi bleeding
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
 
Diaysis john
Diaysis johnDiaysis john
Diaysis john
 
Management of Shock
Management of Shock Management of Shock
Management of Shock
 
Cardiology with pharmacology for nurses
Cardiology with pharmacology for nursesCardiology with pharmacology for nurses
Cardiology with pharmacology for nurses
 
Pancreatic transplant.dr quiyum
Pancreatic transplant.dr quiyumPancreatic transplant.dr quiyum
Pancreatic transplant.dr quiyum
 
Shock nekaba
Shock nekabaShock nekaba
Shock nekaba
 
Portal hypertension
Portal hypertensionPortal hypertension
Portal hypertension
 
Acute Renal Failure1
Acute Renal Failure1Acute Renal Failure1
Acute Renal Failure1
 
Chyluria and its Mangagement
Chyluria and its MangagementChyluria and its Mangagement
Chyluria and its Mangagement
 
Chronic renal failure, surgical management
Chronic renal failure, surgical managementChronic renal failure, surgical management
Chronic renal failure, surgical management
 

Recently uploaded

Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
DrSathishMS1
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
THOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation ActTHOA 2.ppt Human Organ Transplantation Act
THOA 2.ppt Human Organ Transplantation Act
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 

Refractory ascites

  • 1. CHAIR PERSON : PROF.DR.RAVI .K CO CHAIR PERSON:ASSOC.PROF.DR.KAVYA PRESENTER:DR.ASHOKVARDHANREDDY.T
  • 2.  PATHOPHYSIOLOGY OF ASCITES  REFRACTORY ASCITES  DEFINITION,  CAUSES  PATHOPHYSIOLOGY  TREATMENT
  • 3.  Ascites is the most common complication in patients with cirrhosis.  It develops as a consequence of a severe impairment of liver function and portal hypertension.
  • 5. RENAL SODIUM RETENTION OVERFILL OF INTRA VASCULAR VOLUME ASCITES Sympathetic Activity, RAAS
  • 6.  The central event of ascites formation in cirrhosis is a splanchnic arterial vasodilatation secondary to portal hypertension.  1 Backward theory :pressure due to resistance in liver  2 Forward theory :splanchnic bed vaso dilatation.  3 Overflow theory-Increased plasma volume increases hepatic lymph formation.  4 Underfilling theory – Arterial under filling
  • 7.  Clinical examination  Usg abdomen- liver size  portal vein  homogenous – transudate multiple echogenic shadows – exudate Fluid collects first in flanks,right upper quadrant ,para colic gutter , and around liver  Multiple echos ,septations ,fibrous strands indicates ascites unrelated to portal hypertension.
  • 8.  Grade 1-Detectable by ULTRASOUND abdomen.  Grade 2-symmetrical distension of abdomen.shifting dullness present.  Grade 3 :Marked abdominal distension. fluid thrill present
  • 9.  Total ascitic fluid protein is inversely related to portal hypertension.  As the disease severity increases ,protein levels decrease  SBP develops in total ascitic fluid protein <1 g/dl  High concentration of macrophages is found in ascitic fluid  Bloody ascites occurs in 2 % patients
  • 10.  In patients with cirrhosis a complex coagulation process within the ascitic fluid results in intra peritoneal coagulation and primary and secondary fibrinolysis.  The macrophages of ascitic fluid synthesize vasodilatatory substances (e.g., nitric oxide, adreno medullin, vascular endothelial growth factor). The pathophysiologic significance of this finding is unknown.  The concentration of leptin and vascular endothelial growth factor is higher in ascitic fluid than in plasma .
  • 11. Ascitic fluid has anti bacterial activity, which correlates directly with the total ascitic fluid protein concentration . Substances such as complement, fibronectin, cytokines, and are implicated in this effect. Infusion of ascitic fluid within the general circulation is associated with important biologic effects, the most important being intravascular coagulation and fever.
  • 12.  A single layer of mesothelial cells covers the peritoneal surface of the diaphragm over a connective tissue matrix with a very rich plexus of terminal lymphatic vessels (lymphatic lacunae) .  Lacunae are large enough to allow the passage of erythrocytes, connect the peritoneal cavity with the lumen of the terminal lymphatics.
  • 13.  The submesothelial lymphatic plexus drains into parasternal trunks on the ventral thoracic wall, right lymphatic duct, and right subclavian or internal jugular vein. During inspiration, lacunae are emptied During expiration, the gaps open and communication is re established.  The estimated mean rate of ascitic fluid reabsorption is 1.4 L/day, ranging from less than 0.5L to more than 4L.
  • 14.  Furosemide and spironolactone are the most commonly used drugs
  • 15. o Furosemide and spironolactone are most commonly used drugs
  • 16.  Two different approaches for patients with cirrhosis and ascites-  1 step care approach –sodium restriction  spironolactone 100 mg/day  No response in 4 days   200 mg/day  no response in 4 days  400 mg/day
  • 17.  No response at 400 mg spironolactone /day start furosemide 40 mg /day Can be increased to 160 mg /day Dose escalated by 40 mg every 2 days.
  • 18.  Simultaneous administration of Na restriction ,  Spironolactone 100 mg/day  Furosemide 40 mg/day  4 days dose increased to 200 spironolactone + 80 mg furosemide
  • 19.  Complications of diuretics  Renal failure  Hyponatremia  Hepatic encephalopathy  Hypo/hyper kalemia  Hyper uricemia
  • 20.  Furosemide challenge test-  80 mg furosemide iv  urine collection for next 8 hrs  Urine sodium <50 m Eq for 8 hrs is indicative of resistance  Random urine Na/k ratio >1  Indicates 24 hr urine Na excretion >78 m Mol /day.  WORLD JOURNAL OF GASTRO ENTEROLOGY  SENOUSY ETAL , 2009 JANUARY
  • 21.  Once in 2 weeks  Check body weight  BP  Look for orthostatic symptoms  serum electrolytes  Blood urea ,serum creatinine  WORLD JOURNAL OF GASTRO ENTEROLOGY  JANUARY 2009
  • 22.
  • 23.  Refractory ascites applies to the ascites that cannot be mobilized(minimal /no weight loss)despite adherence to sodium restriction(88 m eq/2000 mg/day) or the early recurrence of which (i.e., after therapeutic paracentesis) cannot be prevented by medical therapy.  International ascites club  Arroyo V etal .Hepatology ,1996 .
  • 24.  1 DIURETIC RESISTANT ASCITES:  Loss of body weight <200 g /day after 4 days of treatment or recurrence cannot be prevented even after dietary sodium restriction <50 m eq/day {<90 m Eq/day EASL}  Furosemide 160 mg/day AND  Spironolactone 400 mg/day { SCHIFFS DISEASES OF LIVER}/ 600 mg /day {HARRISONS TEXT BOOK OF INTERNAL MEDICINE} for at least 1 week.  Recurs rapidly after therapeutic paracentesis with in 4 weeks {AASLD}
  • 25.  2 DIURETIC INTRACTABLE ASCITES:  Ascites cannot be mobilised / recurrence cannot be prevented due to diuretic induced complications that precludes use of effective diuretic dose.  Eg –Hepatic encephalopathy in absence of any precipitating cause
  • 26.  Increase in creatinine levels >100% to a value >2 mg %  Decrease in serum sodium level by >10 mEq/L to a concentration <125 mEq/L.  Decrease of serum potassiumlevel to <3 mEq/L or an increase to >6 mEq/L despite appropriate measures to normalize potassium concentration.
  • 27.  Most patients with cirrhosis and ascites with serum creatinine >1.2 mg/dl reflects decrease in renal blood flow and GFR by >50 % .
  • 28.  Renal hypo perfusion   Impairment of access of diuretics to effective sites on the tubular cells  excessive reabsorption of Na + in PCT  Reduced delivery of sodium to ascending limb of loop of henle and the distal nephron
  • 29.  Peritoneo venous shunt.  TIPS(Trans jugular Intrahepatic Portosystemic Shunt).  Therapeutic paracentesis .
  • 30.  Remove ascitic fluid before inserting prosthesis  To avoid massive passage of ascitic fluid in to circulation  Pulmonary edema ,  Variceal bleed,  Intravascular coagulation.
  • 31.  Prophylactic administration of anti staphylococcal antibiotics is recommended atleast for 3 days.
  • 32. .
  • 33.
  • 34. Passage of ascitic fluid from abdominal cavity to systemic circulation Sustained expansion of circulating blood volume Renin,nor epinephrine,ADH, response to diuretics Its very good that patient feels better immediately,and it appears rational therapy for refractory ascites …….BUT
  • 35.  40 % obstruction of shunt with in 1 yr  {Fibrin deposits in valve / catheter,thrombus in venous limb of prosthesis, thrombus in SVC causing obstruction}  10 % small bowel obstruction in long term {intra peritoneal fibrosis}
  • 36.  Remove the prosthesis and insert new one
  • 37.  1 st described by CELSUS in 20 B.C  Ludvig van beethoven in 1827 received large volume paracentesis ….2 days after which he expired.
  • 38.
  • 39.  NECESSITY –  10-20 % of patients are diuretic resistant.  Complications are high with diuretics.  Diuretics take time to reduce ascites.
  • 40.  Therapeutic paracentesis is considered the best therapy for tense ascites in cirrhosis .  It considerably shortens hospital stay ,the cost of treatment, incidence of complications during hospitalization than among those treated with diuretics .
  • 41.  1-  Repeated large volume paracentesis.  Ascites can leak in to abdominal wall/outside.  2-  Total paracentesis  Fluid is removed at once  Less complication rate
  • 42.
  • 43.  7 cm length  17 G  Blunt edged cannula with side holes  Left lower quadrant  To be connected to suction pump,30 – 60 mins( free flow of ascitic fluid is recommended now)  Precaution – patient should recline on opposite side for 2 hrs to prevent leakage of ascitic fluid
  • 44.
  • 45.  Few studies –no apparent major changes in circulatory function  Arterial pressure  PR – No change  Ascites disappears  Creatinine and electrolytes –no change
  • 46.  Intra thoracic pressure Circulatory function  Stroke volume,cardiac output  cardio pulmonary pressure , Renin
  • 47.  plasma renin levels which peaks on 6  th day of paracentesis leads to angiotensin II,nor epinephrine  vaso constriction of intrahepatic vessels-thereby resistance portal pressure 
  • 48.  Patients admitted for tense ascites and not on treatment and in 1 week hospital stay-16 %  Paracentesis induced circulatory dysfunction in patients not on plasma volume expansion -75 %  Patients on polygeline {8g/l ascitic fluid}-33- 38 %  Patients on albumin {8g/l ascitic fluid}-11- 18%
  • 49.  If amount drained is <5 l – incidence is 16% with albumin vs 18 % with synthetic plasma expander .  If 5-9 l- incidence 19% vs 30 %  >9 l 52 % with synthetic plasma expanders.
  • 50.  Risk of peritoneal bleeding 0.5-1 %  Leakage of ascitic fluid from tap site…managed by z technique.  PICD (Paracentesis induced circulatory dysfunction.)  Plasma renin increase > 50 % of pre treatment value to above 4 ng/ml on 6 th day after paracentesis.
  • 51.  Spontaneous bacterial peritonitis  Creatinine >3 mg/dl  Severe hepatic encephalopathy  Hypotension  Disseminated intra vascular coagulation  Caution in patients with abdominal adhesions
  • 52.  Albumin infusion  Incidence of Hyponatremia 3.8 %  renal impairment -0%  No plasma expander-  Hyponatremia – 17 %  Renal impairment 11 %
  • 53.  If we drain < 5 l ascitic fluid –  less expensive synthetic plasma expanders -8g/l ascitic fluid can be used If > 5 l is drained albumin infusion is advised 8 g /l 50% immediately after paracentesis 6 hrs 50 % to be given Diuretics to be continued If BUN and serum creatinine are normal – 200 mg / day spiranolactone or 40 mg /day furosemide + 100 mg /day spironolactone …..
  • 54. paracentesis Leveen shunt Ascites episodes 125 38 Lvs obstruction 40 % in 1 yr Days in hospital 48 +/-6 44+/- 6 Survival 1 yr 57 % 44%
  • 55.  Innovative idea of usage of cvp catheter for drainage of ascitic fluid was tried to reduce the hospitalisation rate ,and so morbidity  Shahram agah,sahar tavakoli,Hajar nikbakth,Mehrdokht Najafi,Abdolreza al agha  Colorectal research center ,IRAN UNIVERSITY OF MEDICAL SCIENCES
  • 56.  Precise percussion and point of highest fluid accumulation should be marked for puncture site.  Local anesthesia with 5-10 ml of 2 % lignocaine inj.  Punctured using 18 G needle  Perpendicular to skin
  • 57.  Guide wire passed through needle.  Remove the needle .  Pass the catheter through guide wire till wing meet the skin .  catheter outlet attached to urine bag .  Drainage started at the rate of 250 -500 ml/hr.  Vital signs checked every 15 mins once during procedure.  8 g Albumin is infused for 1 l of ascitic fluid drained.
  • 58.  After complete drainage of ascitic fluid  {< 100 ml fluid drained /day}.  All patients were prescribed diuretics ,low sodium diet on followed up.
  • 59.  Re admission rate was 1.9 in 1 yr follow up  (2-4 times in routene paracentesis)  Serum sodium showed no significant change ,  Potassium – no significant change  Creatinine decreased with in 24 hrs.
  • 60.
  • 61.
  • 62.  Trans jugular intra hepaic portosystemicshunt   Endogenous vaso constrictor system  Renal function , GFR,response to diuretics  Lymph formation in liver and other splanchnic organs
  • 63.  marked in renin, aldosterone with in 1 week  ADH and Nor epinephrine in 2 weeks  GFR increases ,  urinary excretion of Na increases in 1-2 weeks  Free water clearance
  • 64.  TIPS porto caval gradient  In 358 patients with refractory ascites with TIPS  Porto caval gradient decreased from 20.9 10 mm Hg  Portal venous pressure 29.4 mm Hg 21.8 mm Hg  Ascites resolves in 1-3 months  10 % patients doesn’t respond to TIPS  Diuretics are required in >95 % cases
  • 65.  TOTAL BILIRUBIN >5 mg/dl  PT INR>2  CHILD PUGH SCORE>11  MELD SCORE >18  HEPATIC ENCEPHALOPATHY >/= 2  INFECTIONS  RENAL FAILURE  CARDIOPULMONARY DECOMPENSATION
  • 66.  Most common – hepatic encephalopathy  Occurs in > 40 % patients  Responds to standard therapy  May require to decrease the stent size  Early mortality {with in 30 days} occurs in 12 %  Late mortality in 40 %
  • 67.  Worsening of Liver function tests due to liver ischemia due to diversion of portal blood to systemic circulation  Cardiac failure  Migration of stent to right heart or lung  Endo tipssitis  Transient intra vascular hemolysis  Reference –API Medicine update ..Aabha nagral
  • 68. study Type of ascites Control of ascites Hepatic encephalop athy survival LEBREC etal 1994 Refractory ascites Better with TIPS NO difference Worse with TIPS ROSSLE etal Refractory & recidivant Better with TIPS No difference Better with TIPS GINES etal Refractory Better with TIPS Worse with TIPS No difference SANYAL etal Refractory Better with TIPS Worse with TIPS No difference SALERNO etal2004 Refractory & recidivant Better with TIPS Worse with TIPS Better with TIPS
  • 69.  TIPS changes course of cirrhosis from ascites to hepatic encephalopathy without improving overall results of paracentesis , in relation to length of hospitalisation .
  • 70.  Medical therapy –  Beta blockers contra indicated ( hypotension)  Midodrine 7.5 mg tid can be started  urine output  urine sodium  mean arterial pressure  Diuretic resistant diuretic sensitive
  • 71.  Refractoriy ascites  discontinue betablockers,  add midodrine 7.5 mg  tid  If not responding  Consider 1 serial therapeutic paracentesis  2 liver transplant  3 TIPS  4 experimental medical treatment
  • 72.  Large volume therapeutic paracentesis-{ atleast 5 L}  Total paracentesis is recommended  Once in 2 weeks or once in 1 week  Colloid replacement- In a randomised control study 105 patients with tense ascites-  Albumin 1g/L vs without albumin infusion was studied
  • 73.  Significant increase in renin ,  creatinine,  serum electrolytes are observed without albumin infusion.  But no more clinical morbidity and mortality
  • 74. o hr Terlpressin iv 1 mg starting of paracentesis 8 hr iv 1 mg repeat +tab midodrine 5 mg tid 16 hr iv 1 mg repeat EQUIVALENT to albumin in suppressing renin
  • 75.  Chronic therapeutic paracentesis is reserved for only 10 % patients who fail diuretics  As it causes hypo proteinemia,  Malnutrition  Increased infections  Prognosis of refractory ascites –  Bad.21 % die in 6 months
  • 76.  TIPS vs Large volume therapeutic paracentesis  Significant survival advantage  Better control of ascites  More chances of encephalopathy  Caution- patients with renal parenchymal disease on dialysis may not respond well to TIPS  Do not with held diuretics after TIPS  New entry- poly tetra fluoro ethylene coated Stent is better ,patency duration is increased,greater survival;
  • 77.  Why?  Poor long term patency  Increased infections  No increased survival compared to medical therapy  Only in patients who are not candidates for TIPS/liver transplant/not fit for serial therapeutic paracentesis
  • 78.  1 retrospective study on efficacy of weekly albumin infusion of 50 g in reducing weight in patients with refractory ascites who are not candidates for TIPS ….result awaited  Pilot Randomised control study -0.075 mg oral clonidine bid vs placebo in patients with cirrhosis ,with ascites and plasma nor Epinephrine> 300 pg/ml--- more rapid mobilisation of ascites with fewer complications
  • 79.  3 pilot Randomised control studies  Paracentesis + albumin  Vs  Clondine + spironolactone  In patients with refractory ascites and plasma nor epinephrine >300 pg/ml  Result – fewer hospitalisation in latter group .
  • 80.
  • 81. Device that drains ascitic fluid into urinary bladder. ALFA pump system (Automated low flow ascites pump). Flow : catheter in abdominal cavity subcutaneously inserted battery powered pump catheter connected to bladder. Pump is recharged wirelessly through skin Removes 5 L per charge.
  • 82.  Severe irritation in bladder Recurrent urinary tract infections. Pyelo nephritis Not approved for practise.
  • 83.  Median survival period for refractory ascites is 6 months  1 st best option is liver transplant  MELD score >18  Hyponatremia <130 mEq/l  LOW Mean arterial pressure  Low urine sodium <50 m eq/l  High child pughscore >11  All determine duration of survival
  • 84.  LVP is the 1 st line treatment  Diuretics must be discontinued if dys electrolytemia/renal failure/hepatic encephalopathy occurs.Continue diuretics only when urine sodium >30 mMol/l  V2 receptor antagonists – satavaptan + fixed dose diuretics is under phase II trials  Improves Na levels,increases weight loss,decreases recurrence of ascites.  TIPS is recommended only if very frequent requirement of LVP/ineffective paracentesis (loculated)
  • 85.  Role of aquaretics  phase III clinical trials –satavaptan + diuretics showed no further improvement in control of ascites  Increased morbidity and mortality was also observed  Recently Tolvaptan is approved for management of refractory ascites..
  • 86.  Forty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long term administration of midodrine plus standard medical therapy (n = 20) or standard medical therapy alone (n = 20) in a randomized controlled trial at a tertiary centre. Virendra singh etal …PGIMER
  • 87.  A significant increase in urinary volume, urinary sodium excretion, mean arterial pressure, and decrease in plasma renin activity (p <0.05) was noted after 1 month of midodrine administration.  There was also a significant decrease in cardiac output and an increase in systemic vascular resistance after midodrine therapy at 3 months (p <0.05)
  • 88. There was no change in glomerular filtration rate and model for end-stage liver disease (MELD) score. Midodrine addition is superior to standard medical therapy alone in the control of ascites (p = 0.013) at 3 months. The mortality rate in the standard medical therapy group was significantly higher than the midodrine group (p <0.046). There was no significant difference in the frequency of various complications at the end of follow-up.
  • 89.  ANNALS OF HEPATOLOGY ..Amarapurkar etal  Back ground- use of covered TIPS was shown to improve the shunt patency rate over uncovered TIPS.Retrospective analysis was performed to assess efficacy of both  Methods-over 10 yr period,selected patients who require LVP atleast 2 times in a month,or intolrant to LVP,or unwilling to undergo further LVP were treated with TIPS
  • 90.  12 PATIENTS 11 PATIENTS  Uncovered TIPS PTFE covered TIPS  Age 56.1+/_4.5 yrs 55.8+/_5.2 yrs  Male : female-5:1 male :female-8:3  Followed up with –clinical examination,USG abdomen,doppler examination ,every monthly for 3 months,and every 3 monthly thereafter.
  • 91.  Clinical success= disappearance of ascites in 1 month  Technical success =post TIPS reduction of PPG (porto systemic pressure gradient) <12 mm Hg.  Appearance of encephalopathy  TIPS dysfunction= >50 %reduction in flow velocity ,> 50 % shunt stenosis,or increase in PPG> 12mm Hg
  • 92. GROUP A GROUP B CLINICAL SUCCESS 63.3% 81.8% TECHNICAL SUCCESS 63.3% 81.8% HEPATIC NCEPHALOPATHY 60% 54.4% MORTALITY AT 1 YR 70% 63.3% TIPS DYSFUNCTION REQUIRING RE INTERVENTION 50% 0%
  • 93.  Harrisons text book of internal medicine 18th edition  Schiffs diseases of liver 11th edition.  Sherlock’s diseases of liver and biliary tract 12th edition  AASLD guide lines 2013  EASL guidelines of liver disease 2012  Indian journal of gastro enterology. .volume 33,isssue4 ,august 2014.  Clinical gastroenterology by Rajiv mehta 3rd edition.
  • 94. Thanks to • Dr.RAVI .K professor of medicine • Dr.SUSHRUTH Surgical gastro enterologist. PMSSY